8-K: Processa Pharmaceuticals Secures $6.3 Million in Public Offering to Advance Cancer Therapy

Processa Pharmaceuticals, Inc. announced the pricing and closing of a public offering raising approximately $6.3 million, intended to fund its Phase 2 clinical trial for NGC-Cap and for general corporate purposes.

Summary

• Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) completed a public offering that included 14,310,000 shares of common stock and 13,690,000 pre-funded warrants.
• The offering also included common warrants to purchase up to 28,000,000 shares of common stock.
• The combined public offering price was $0.25 per share (or pre-funded warrant) and associated common warrant.
• Common Warrants have an exercise price of $0.25 per share, are immediately exercisable, and expire five years after issuance.
• Pre-Funded Warrants have a nominal exercise price of $0.0001, are immediately exercisable, and remain exercisable until fully exercised.
• H.C. Wainwright & Co. LLC served as the exclusive placement agent for the offering.
• The company agreed to pay the Placement Agent a 7.0% cash fee of the gross proceeds, a non-accountable expense allowance of up to $50,000, legal fees up to $100,000, and clearing expenses of $15,950.
• Additionally, the Placement Agent received warrants to purchase 1,120,000 shares of common stock at an exercise price of $0.3125.
• The offering closed on June 18, 2025, generating approximately $6.3 million in gross proceeds, excluding any proceeds from the exercise of common warrants.
• Net proceeds are earmarked for continuing the Phase 2 clinical trial of NGC-Cap, working capital, and other general corporate purposes.
• The company has a 60-day lock-up period on issuing common stock or equivalents and a 6-month prohibition on variable rate transactions, with certain exceptions after 90 days for equity lines or at-the-market offerings with the Placement Agent.

Sentiment

Score: 4

Explanation: While the capital raise provides crucial funding for the company's clinical development, the highly dilutive nature of the offering (low share price, significant warrant issuance, and substantial agent fees) suggests a challenging financial position and could negatively impact existing shareholder value. The positive is securing funds for a key clinical trial, but the terms reflect a high cost of capital.

Positives

• The offering successfully secured approximately $6.3 million in gross proceeds, providing essential capital for the company's operations.
• Funds are specifically allocated to continue the Phase 2 clinical trial of NGC-Cap, indicating progress in the development of a key oncology therapy.
• The offering was conducted under an effective registration statement, facilitating the issuance and potential resale of shares and warrants.

Negatives

• The offering price of $0.25 per share is very low, suggesting significant dilution for existing shareholders.
• The issuance of a substantial number of common warrants (28,000,000) and placement agent warrants (1,120,000) could lead to further dilution upon their exercise.
• High fees and expenses paid to the placement agent (7.0% cash fee, plus allowances and reimbursements) reduce the net proceeds available to the company.

Risks

• The uncertain nature of forward-looking statements means actual results may differ materially from current expectations.
• Risks are associated with the intended use of proceeds, including the success of the Phase 2 clinical trial for NGC-Cap.
• Hedging activities by purchasers, including short sales or derivative transactions, could negatively impact the market price of the company's publicly-traded securities.
• Potential for significant future dilution from the exercise of the large number of outstanding warrants.

Future Outlook

Processa Pharmaceuticals intends to utilize the net proceeds from this offering to continue its Phase 2 clinical trial for NGC-Cap and for general working capital and corporate purposes. The company has also committed to a 60-day lock-up period on further equity issuances and a 6-month restriction on variable rate transactions, with specific exceptions for equity lines and at-the-market offerings with the placement agent after 90 days.

Management Comments

• The Company anticipates using the net proceeds from the Offering to continue the Phase 2 clinical trial of NGC-Cap and for working capital and other general corporate purposes.

Industry Context

This capital raise is typical for a clinical-stage pharmaceutical company like Processa Pharmaceuticals, which requires significant funding to advance its drug candidates through costly and lengthy clinical trials. The use of common stock and warrants at a low price point is often seen in the biotech sector, especially for companies with early-stage assets or those facing valuation challenges, as a means to secure necessary capital for research and development, particularly for a Phase 2 trial which is a critical milestone in drug development.

Comparison to Industry Standards

• The offering price of $0.25 per share, coupled with the issuance of a large number of warrants, indicates a highly dilutive financing structure. While such dilutive financings are not uncommon for small-cap, clinical-stage biotech companies, they are generally less favorable compared to non-dilutive or less dilutive funding options available to more mature pharmaceutical companies with approved products or late-stage pipelines.
• The significant fees and expenses paid to the placement agent (7.0% cash fee plus additional allowances) are on the higher end of industry standards for public offerings, reflecting the perceived risk or difficulty in raising capital for companies at this stage and valuation.

Stakeholder Impact

• Shareholders: Experience significant dilution due to the issuance of a large number of new shares and warrants at a low price. Potential for further dilution upon the exercise of warrants.
• Employees: Benefit from the continued funding of operations and clinical trials, which supports job security and the company's long-term prospects.
• Customers: Not directly impacted by this financing event, as the company is clinical-stage and does not yet have commercial products.
• Suppliers/Creditors: Improved ability for the company to meet its financial obligations due to the influx of new capital.

Next Steps

• Continue the Phase 2 clinical trial for NGC-Cap.
• Utilize net proceeds for working capital and general corporate purposes.
• Maintain listing on Nasdaq Capital Market and apply to list all newly issued shares and warrant shares.
• Adhere to the 60-day lock-up period on new equity issuances and 6-month prohibition on variable rate transactions.

Key Dates

Recommendation

Keywords

Processa Pharmaceuticals, PCSA, Public Offering, Capital Raise, Common Stock, Warrants, Pre-Funded Warrants, Clinical-Stage Pharmaceutical, NGC-Cap, Phase 2 Clinical Trial, SEC Filing, Form 8-K, H.C. Wainwright & Co., Biotechnology, Oncology, Drug Development